Bioequivalence and Bioavailability Forum

Subject	Author	Posted	Rep.	last R.	Views
‘alpha’ of scaled ABE? ‘alpha’ of scaled ABE? ’alpha’ of scaled ABE: design N=24, 48 adaptive design without adjustment α adjustment? iteratively adjusted alpha throw away our sample size tables? if real regulators don’t care? adjusting α missing letter PowerTOST: sampleN.scABEL.ad() PowerTOST: sampleN.scABEL.ad() Molins et al. (2017) target α in sim’s? target α in sim’s? If it is real: results having alpha fixed swr fixed swr Yes but no but yes but no but…	d_labes	2013-03-15 15:56	21	2024-11-08 14:34	32,932
data management data management	Imph	2024-03-14 09:57	1	2024-03-14 15:47	3,179
homoscedasticity assumption in RSABE method heteroscedasticity in RSABE (and ABEL) heteroscedasticity in RSABE (and ABEL) homoscedasticity assumption in RSABE method Asking a pupil Asking a pupil	WinnieH	2023-08-18 08:57	5	2023-08-18 17:16	3,954
any SAS or R-macro for 3 period two sequence RSABEIs Use the one for TRTR \| RTRT RSABE R coded by Detlew ‘dlat’ for 3-period full replicate? ‘dlat’ for 3-period full replicate? Likely wrong workaround? a bit corrected workaround THX! Another attempt… complete.cases for dlat and ilat? a bit corrected workaround	Achievwin	2023-07-05 18:38	9	2023-07-10 20:43	5,333
Reference-Scaled Average Bioequivalence FDA: TRT\|RTR instead of TRR\|RTR\|RRT?	Brus	2023-06-06 12:18	1	2023-06-07 10:22	3,099
Upper confidence bound and confidence interval of RSABE	WinnieH	2023-03-21 10:58	0		2,272
Questions on understanding the 4-way RSABE method SAS code Questions on understanding the 4-way RSABE method SAS code Questions on understanding the 4-way RSABE method SAS code	WinnieH	2023-01-04 13:33	2	2023-01-04 15:12	4,054
scale average bioequivalence for parallel design Parallel design: Maybe (‼) in exceptional cases Parallel design: Maybe (‼) in exceptional cases	Mahmoud	2022-06-15 12:33	2	2022-06-15 21:26	3,669
Sample size and power	Helmut	2022-03-28 13:39	0		2,427
Sample Size Efficiency of 4-Period, 2-Seq, 2-Formulation Design Sample Size Efficiency of 4-Period, 2-Seq, 2-Formulation Design Sample Size Efficiency of 4-Period, 2-Seq, 2-Formulation Design NTIDs	Sereng	2022-01-28 19:37	3	2022-01-29 11:19	4,293
FDA: SAS-code for NTIDs FDA: SAS-code for NTIDs	Bebac user	2021-12-06 00:36	1	2021-12-06 09:55	4,172
Inter-subject variability in Full replicate design Inter-subject variability in Full replicate design Inter-subject variability in Full replicate design	MGR	2021-09-30 07:35	2	2021-09-30 13:25	4,591
If we have any methods to widen CI in parallel design with high variance drug? If we have any methods to widen CI in parallel design with high variance drug? If we have any methods to widen CI in parallel design with high variance drug?	libaiyi	2021-02-02 09:39	2	2021-02-02 10:40	4,009
95% upper bound limit as per FDA for fully replicate crossover BE study 95% upper bound limit as per FDA for fully replicate crossover BE study 0.001 > 0 0.001 > 0	yogeshla	2021-01-05 07:01	3	2021-01-05 11:33	4,471
Inflated type I error with fixed widened limits? Inflated type I error with fixed widened limits? Inflated type I error with fixed widened limits? Inflated type I error with fixed widened limits Inflated type I error: Not nice Power of the GCC framework and power of PowerTOST Sample sizes (ignoring the inflated TIE) Bug? “Feature” Inflated type I error with fixed widened limits? Inflated type I error with fixed widened limits Inflated type I error with fixed widened limits Inflated type I error with fixed widened limits Houston, we have a problem! Paradox of tolerance Οὐτοπεία ∨ Εὐτοπεία Uchronia Steampunk Dieselpunk Dieselpunk Steampunk? OT Steampunk? OT PowerTOST 1.5-2.9000 on GitHub	Helmut	2020-11-25 10:50	22	2020-12-23 11:18	13,430